Fluoroquinolones and Cardiovascular Risk: A Systematic Review, Meta-analysis and Network Meta-analysis
ConclusionsOur findings show a significant association between fluoroquinolone use and an increased risk for arrhythmia and cardiovascular mortality. Moxifloxacin ranked with the highest probability for cardiovascular adverse events. Further study is required to determine how to reduce the risk for fluoroquinolone-associated cardiac toxicity.
Source: Drug Safety - Category: Drugs & Pharmacology Source Type: research
More News: Arrhythmia | Avelox | Cardiology | Cardiovascular | Databases & Libraries | Drugs & Pharmacology | Heart | Moxifloxacin | Statistics | Study | Toxicology